이식 환자의 감염 예방

키워드

참고문헌 (94)

1. Fishman JA, "Infection in solid-organ transplant recipients", N Engl J Med, 357, pp.2601~2614 (2007)
2. Tomblyn M, "Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients : a global perspective", Biol Blood Marrow Transplant, 15, pp.1143~1238 (2009)
3. 이동건, "국내자료를 근거로 한 호중구감소성 발열 환자의 경험적 치료 지침", Infection and Chemotherapy, 43(4), pp.285~321 (2011), 대한감염학회
4. Goodrich JM, "Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant", Ann Intern Med, 118, pp.173~178 (1993)
5. Prentice HG, "Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation: European Acyclovir for CMV Prophylaxis Study Group", Lancet, 343, pp.749~753 (1994)
6. Ljungman P, "Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants", Blood, 99, pp.3050~3056 (2002)
7. Boeckh M, "and future strategies", Biol Blood Marrow Transplant, 9, pp.543~558 (2003)
8. Drew WL, "Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients", Curr Opin Infect Dis, 20, pp.408~411 (2007)
9. Tomblyn M, "Guidelines for preventing infectious complications among hematopoietic cell transplant recipients : a global perspective : preface", Bone Marrow Transplant, 44, pp.453~455 (2009)
10. Freeman RB, "Valganciclovir : oral prevention and treatment of cytomegalovirus in the immunocompromised host", Expert Opin Pharmacother, 5, pp.2007~2016 (2004)
11. Ayala E, "Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation", Bone Marrow Transplant, 37, pp.851~856 (2006)
12. Einsele H, "Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation", Blood, 107, pp.3002~3008 (2006)
13. Van der Heiden PL, "Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients", Bone Marrow Transplant, 37, pp.693~698 (2006)
14. Busca A, "Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation", Transpl Infect Dis, 9, pp.102~107 (2007)
15. Allice T, "Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation : implications for the emergence of drug-resistant cytomegalovirus", J Antimicrob Chemother, 63, pp.600~608 (2009)
16. Takenaka K, "Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients", Int J Hematol, 96, pp.94~100 (2012)
17. Nichols WG, "Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products", Blood, 101, pp.4195~4200 (2003)
18. Ljungman P, "unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors", Scand J Infect Dis, 34, pp.347~350 (2002)
19. Bowden RA, "A comparison of filtered leukocyte-reduced and cytomegalovirus(CMV)seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant", Blood, 86, pp.3598~3603 (1995)
20. Ratko TA, "Evidencebased recommendations for the use of WBC-reduced cellular blood components", Transfusion, 41, pp.1310~1319 (2001)
21. Bowden RA, "Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant", Blood, 78, pp.246~250 (1991)
22. Van Prooijen HC, "Prevention of primary transfusionassociated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters", Br J Haematol, 87, pp.144~147 (1994)
23. Small LN, "Preventing post-organ transplantation cytomegalovirus disease with ganciclovir : a meta-analysis comparing prophylactic and preemptive therapies", Clin Infect Dis, 43, pp.869~880 (2006)
24. Potena L, "Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients", J Heart Lung Transplant, 28, pp.461~467 (2009)
25. Potena L, "Cytomegalovirus-associated allograft rejection in heart transplant patients", Curr Opin Infect Dis, 20, pp.425~431 (2007)
26. Kotton CN, "International consensus guidelines on the management of cytomegalovirus in solid organ transplantation", Transplantation, 89, pp.779~795 (2010)
27. Kalil AC, "Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy", PLoS One, 4, pp.5512~ (2009)
28. Andrews PA, "Summary of the British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation", Transplantation, 92, pp.1181~1187 (2011)
29. Kalil AC, "Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation : direct and indirect treatment comparison meta-analysis", Clin Infect Dis, 52, pp.313~321 (2011)
30. Dignani MC, "Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation", Bone Marrow Transplant, 29, pp.263~267 (2002)
31. Eisen D, "Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy", Bone Marrow Transplant, 31, pp.51~55 (2003)
32. De Boer MG, "An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?", Clin Infect Dis, 44, pp.1143~1149 (2007)
33. Schmoldt S, "Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation", J Clin Microbiol, 46, pp.966~971 (2008)
34. Sassi M, "Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis : implications for transmission and virulence", Clin Infect Dis, 54, pp.1437~1444 (2012)
35. Phipps LM, "Nosocomial Pneumocystis jirovecii pneumonia : lessons from a cluster in kidney transplant recipients", Transplantation, 92, pp.1327~1334 (2011)
36. Fishman JA, "Prevention of infection due to Pneumocystis carinii", Antimicrob Agents Chemother, 42, pp.995~1004 (1998)
37. De Castro N, "Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation : a 6-year retrospective study", Bone Marrow Transplant, 36, pp.879~883 (2005)
38. Rodriguez M, "in human immunodeficiency virusnegative immunocompromised patients", Clin Microbiol Rev, 17, pp.770~782 (2004)
39. Centers for Disease Control and Prevention ; Infectious Disease Society of America ; American Society of Blood and Marrow Transplantation, "Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients", MMWR Recomm Rep, 49(10), pp.1~125 (2000)
40. Lyytikäinen O, "Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation", Bone Marrow Transplant, 17, pp.1057~1059 (1996)
41. Tuan IZ, "Pneumocystis carinii pneumonitis following bone marrow transplantation", Bone Marrow Transplant, 10, pp.267~272 (1992)
42. Martin SI, "AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients", Am J Transplant, 9(4), pp.227~233 (2009)
43. Fishman JA, "Prevention of infection caused by Pneumocystis carinii in transplant recipients", Clin Infect Dis, 33, pp.1397~1405 (2001)
44. Kontoyiannis DP, "Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database", Clin Infect Dis, 50, pp.1091~1100 (2010)
45. Marr KA, "Fungal infection prevention after hematopoietic cell transplantation", Bone Marrow Transplant, 44, pp.483~487 (2009)
46. Pfaller MA, "Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing", J Clin Microbiol, 45, pp.1735~1745 (2007)
47. Pfaller MA, "Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002", J Clin Microbiol, 42, pp.3142~3146 (2004)
48. Van Burik JA, "Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation", Clin Infect Dis, 39, pp.1407~1416 (2004)
49. Matsue K, "Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin", Clin Infect Dis, 42, pp.753~757 (2006)
50. Madureira A, "Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin", Int J Antimicrob Agents, 30, pp.551~554 (2007)
51. Oren I, "A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients", Bone Marrow Transplant, 38, pp.127~134 (2006)
52. Winston DJ, "Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial", Ann Intern Med, 138, pp.705~713 (2003)
53. Marr KA, "Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants", Blood, 103, pp.1527~1533 (2004)
54. Hof H., "A new, broad-spectrum azole antifungal: posaconazole: mechanisms of action and resistance, spectrum of activity", Mycoses, 49(1), pp.2~6 (2006)
55. Boucher HW, "Newer systemic antifungal agents: pharmacokinetics, safety and efficacy", Drugs, 64, pp.1997~2020 (2004)
56. Ullmann AJ, "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease", N Engl J Med, 356, pp.335~347 (2007)
57. De la Cámara R, "Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT", Bone Marrow Transplant, 45, pp.925~932 (2010)
58. O'Sullivan AK, "Costeffectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease", Am J Health Syst Pharm, 69, pp.149~156 (2012)
59. Ananda-Rajah MR, "Making sense of posaconazole therapeutic drug monitoring : a practical approach", Curr Opin Infect Dis, 25, pp.605~611 (2012)
60. Cordonnier C, "Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients", Haematologica, 96, pp.9~10 (2011)
61. Cordonnier C, "Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients : results of the VOSIFI Study", Haematologica, 95, pp.1762~1768 (2010)
62. Pappas PG, "Invasive fungal infections among organ transplant recipients : results of the Transplant-Associated Infection Surveillance Network(TRANSNET)", Clin Infect Dis, 50, pp.1101~1111 (2010)
63. Winston DJ, "Prophylactic fluconazole in liver transplant recipients: a randomized, doubleblind, placebo-controlled trial", Ann Intern Med, 131, pp.729~737 (1999)
64. Lumbreras C, "Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation", J Infect Dis, 174, pp.583~588 (1996)
65. Cruciani M, "Antifungal prophylaxis in liver transplant patients : a systematic review and meta-analysis", Liver Transpl, 12, pp.850~858 (2006)
66. Playford EG, "Antifungal agents for preventing fungal infections in solid organ transplant recipients", Cochrane Database Syst Rev, pp.004291~ (2004)
67. Hadley S, "Outcomes of antifungal prophylaxis in high-risk liver transplant recipients", Transpl Infect Dis, 11, pp.40~48 (2009)
68. Playford EG, "Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients", Eur J Clin Microbiol Infect Dis, 25, pp.549~561 (2006)
69. Brizendine KD, "Antifungal prophylaxis in solid organ transplant recipients", Expert Rev Anti Infect Ther, 9, pp.571~581 (2011)
70. Muñoz P, "Risk factors of invasive aspergillosis after heart transplantation : protective role of oral itraconazole prophylaxis", J Transplant, 4, pp.636~643 (2004)
71. Biancofiore G, "Antifungal prophylaxis in liver transplant recipients : a randomized placebo-controlled study", Transpl Int, 15, pp.341~347 (2002)
72. Winston DJ, "Randomized controlled trial of oral itraconazole solution versus intravenous", oral fluconazole for prevention of fungal infections in liver transplant recipients, 2002, pp.74, 688~695
73. Sharpe MD, "Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study", Transplantation, 76, pp.977~983 (2003)
74. Drew RH, "Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients", Transplantation, 77, pp.232~237 (2004)
75. Drew R., "Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections", Int J Antimicrob Agents, 27(1), pp.36~44 (2006)
76. Akan H, "Tuberculosis in stem cell transplant patients", J Hosp Infect, 62, pp.421~426 (2006)
77. Yuen KY, "Tuberculosis in blood and marrow transplant recipients", Hematol Oncol, 20, pp.51~62 (2002)
78. Korean Guidelines for Tuberculosis, "Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention", pp.1~218 (2011)
79. Torre-Cisneros J, "Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort", Clin Infect Dis, 48, pp.1657~1665 (2009)
80. Ha YE, "Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients", Transpl Infect Dis, 14, pp.626~634 (2012)
81. Muñoz P, Rodríguez C, "Mycobacterium tuberculosis infection in recipients of solid organ transplants", Clin Infect Dis, 40, pp.581~587 (2005)
82. Ljungman P, "Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine", J Infect Dis, 159, pp.610~615 (1989)
83. Ljungman P, "Response to tetanus toxoid immunization after allogeneic bone marrow transplantation", J Infect Dis, 162, pp.496~500 (1990)
84. Pauksen K, "Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation", Bone Marrow Transplant, 9, pp.427~432 (1992)
85. Parkman R, "Immunological reconstitution following hematopoietic stem cell transplantation, In Thomas’s Hematopoietic Cell Transplantation. 3rd edition", pp.853~861 (2003), Blackwell Science
86. Storek J, "Immunological reconstitution after hematopoietic stem cell transplantation, In Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd edition", pp.194~226 (2004), Cambridge University Press
87. Molrine DC, "Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation", Blood, 101, pp.831~836 (2003)
88. Molrine DC, "Donor immunization with Haemophilus influenzae type b(HIB)-conjugate vaccine in allogeneic bone marrow transplantation", Blood, 87, pp.3012~3018 (1996)
89. Guinan EC, "Polysaccharide conjugate vaccine responses in bone marrow transplant patients", Transplantation, 57, pp.677~684 (1994)
90. Kumar D, "A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients", Clin Infect Dis, 45, pp.1576~1582 (2007)
91. Cordonnier C, "Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation", Clin Infect Dis, 48, pp.1392~1401 (2009)
92. Cordonnier C, "Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients : results from the EBMT IDWP01 trial", Vaccine, 28, pp.2730~2734 (2010)
93. Danzinger-Isakov L, "AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients", Am J Transplant, 9(4), pp.258~262 (2009)
94. Cordero E, "Influenza vaccination in solid-organ transplant recipients", Curr Opin Organ Transplant, 17, pp.601~608 (2012)

관련 논문AI추천